Login / Signup

Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.

Lorenzo PiemontiBart KeymeulenPieter GillardThomas LinnEmanuele BosiLudger RosePozzilli PaoloFrancesco GiorginoEfisio CossuLuisa DaffonchioGiovanni GoisisPier Adelchi RuffiniAnna Rita MauriziFlavio MantelliMarcello Allegretti
Published in: Diabetes, obesity & metabolism (2022)
In newly diagnosed patients with type 1 diabetes, short-term LDX treatment had no appreciable effect on preserving residual beta cell function.
Keyphrases
  • double blind
  • placebo controlled
  • newly diagnosed
  • clinical trial
  • type diabetes
  • phase iii
  • study protocol
  • phase ii
  • cell migration
  • glycemic control
  • combination therapy
  • metabolic syndrome
  • weight loss
  • replacement therapy